- Open Access
Novel targeted therapies and immunotherapy for advanced thyroid cancers
© The Author(s). 2018
- Received: 19 September 2017
- Accepted: 1 February 2018
- Published: 19 February 2018
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, around 30% of medullary thyroid cancer (MTC) cases show resistance after surgery. The evolving understanding of disease-specific molecular therapeutic targets has led to the approval of two targeted therapies (Sorafenib and Lenvatinib) for RAI refractory DTC and another two drugs (Vandetanib and Cabozantinib) for MTC. These advanced therapies exert their effects by blocking the MAPK pathway, which has been widely correlated to different types of thyroid cancers. While these drugs remain reserved for thyroid cancer patients who failed all treatment options, their ability to improve patients’ overall survival remain hindered by their low efficacy and other molecular factors. Among these factors is the tumor’s ability to activate parallel proliferative signaling pathways other than the cascades blocked by these drugs, along with overexpression of some tyrosine kinase receptors (TKR). These facts urge the search for novel different treatment strategies for advanced thyroid cases beyond these drugs. Furthermore, the growing knowledge of the dynamic immune system interaction with tumor microenvironment has revolutionized the cancer immune therapy field. In this review, we aim to discuss the molecular escape mechanisms of thyroid tumors from these drugs. We also highlight novel therapeutic options targeting other pathways than MAPK, including PI3K pathway, ALK translocations and HER2/3 receptors and their clinical impact. We also aim to discuss the usage of targeted therapy in restoring thyroid tumor sensitivity to RAI, and finally turn to extensively discuss the role of immunotherapy as a potential alternative treatment option for advanced thyroid diseases.
For the past several decades thyroid cancer has been the most common endocrine tumor, with a ~ 5% increase in incidence each year in the USA [1, 2]. The vast majority of thyroid cancers arise from thyroid follicular cells (93%) and are well-differentiated (DTC). Most of these are categorized on histologic grounds as being papillary thyroid cancers (PTC), or less commonly as follicular thyroid cancers (FTC), the latter being associated with a worse prognosis. Poorly differentiated forms with even more aggressive clinical behavior are relatively uncommon and the highly fatal anaplastic thyroid cancers (ATC) are fortunately rare [3, 4]. Parafollicular cell-derived medullary thyroid cancers (MTC) are also rare, comprising ~ 3% of thyroid carcinomas .
A small fraction (< 10%) of DTC as well as many MTCs and almost all ATCs are not cured by standard therapy, instead spreading to distant metastatic sites. If grouped together as “advanced thyroid cancers,” patients with these aggressive forms have a less than 50% 5 year survival rate in contrast to the ~ 98% 5-year survival for iodine-sensitive DTC patients .
Recently, a number of scientific advances have illuminated some of the molecular pathways responsible for thyroid cancer. This growing knowledge raises the hope that it will soon be possible to develop specific therapeutics tailored to these molecular changes . While multiple kinase inhibitor drugs (MKIs) targeting MAPK pathway have had some clinical benefit, improvements in overall survival is still debatable . Both the presence of tumoral intrinsic resistance mechanisms to these MKIs, as well as the systemic toxicity of the drugs have limited their clinical benefits . Therefore, novel approaches must be explored for advanced thyroid cancers.
This review article considers the major therapeutic strategies currently being investigated in the field of advanced thyroid cancer, focusing on approaches with not only pre-clinical but also clinical trial data. We aim to discuss novel and experimental MKIs for advanced thyroid cancers, radioactive iodine (RAI) resensitization and finally a section on immunotherapy.
It is to be noted that search strategy and selection criteria and references for this Review were identified through searches of PubMed, “clinicaltrials.gov”, and oncology conferences’ websites with the search terms “thyroid cancer”, “targeted therapy”, “MAPK”, “radioactive iodine refractory thyroid cancer”, and “immunotherapy for thyroid cancer” since inception. Only papers published in English were reviewed. The references were included based on their pertinence to the scope of this Review
Mutations in thyroid cancers
Thyroid cancer type
Description and significance
Differentiated thyroid cancers
B-RAF point mutations (particularly glutamate substitution for valine at residue 600, V600E) are present in 30–70% of patients with PTC
RAS oncogene mutations are manifested in 15–20% of PTC and 40–50% of FTC
RET/PTC1 and RET/PTC3 together comprise > 90% of RET/PTC mutations in thyroid cancer); RET/PTC2 represents less than 5%. Combined, RET/PTC rearrangements are found in ~ 13% of PTC
PAX8 drives the expression of many thyroid-specific genes such as those encoding thyroglobulin, the sodium iodide symporter and thyroid peroxidase. The PAX8-PPARγ translocations are found in 35% of FTC and vascular invasion and tumor proliferation have been linked to these translocations.
Telomerase reverse transcriptase gene (TERT) mutations
Found to be overexpressed in DTC; 11% of FTC and 16–40% of PTC (frequently in association to B-RAF mutations) were found to bear TERT mutations. Coexistence of TERT with BRAF mutation was concluded to have the worst prognosis for DTC patients especially those with PTC subtype . However, studies examining TERT as a therapeutic target are lacking.
PIk3CA gene encodes for catalytic subunits in PI3K leading to activating the proliferative cascade of PI3K/AKT pathway. Increased copy numbers of this gene has been found in 24% of FTC and 42% of ATC.
PTEN normally antagonizes and terminates the signaling of the PI3K/Akt pathway. It was found that around 12% of ATC exhibit mutated or deleted PTEN genes and hence over activation of the proliferative PI3k pathway and more tumoral aggressiveness.
Medullary thyroid cancers
> 60% of MTC have been linked to somatic RET oncogene mutations.
Other MKIs for MAPK are being tested for different types of thyroid cancer but at the time of writing this article, none have reached phase III trials
Partial response RR (%)
Progression-free survival PFS (months)
Adverse effects (%)
VEGFR, PDGFR, c-kit
starting dose of 5 mg twice daily
Fatigue (50%), diarrhea (48%), nausea (33%), anorexia (30%), hypertension (28%), stomatitis (25%), weight loss (25%), and headache (22%)
32 patients, 8 of them due to treatment side effects
VEGFR, PDGFR, c-kit
125 mg/day orally for up to 48 weeks
Diarrhea (59%), hypertension (56%), fatigue (46%), and weight loss (40%)
61 patients, 12 of them due to treatment side effects
PDGFR, FLT3, c-kit, VEGFR, RET
37.5 mg/day orally
Neutropenia (34%), fatigue (11%), HFS (17%), diarrhea (17%), and leukopenia (31%)
4 patients due to treatment side effects
VEGFR, PDGFR, c-kit
800 mg/day orally in 4-week cycle
Fatigue (78%), skin and hair hypopigmentation (75%), diarrhea (73%), and nausea (73%)
27 patients, 2 of them due to treatment side effects
FGFR, and (VEGFR)
500 mg/day orally for five consecutive days, followed by a 2-day rest every week.
Diarrhea (54%), anorexia (36%), vomiting (26%), fatigue (23%), and nausea (21%)
BCR-ABL, PDGFR-α, PDGFR-β, c-fms, c-Kit, and RET
600 mg/day orally
Hypothyroidism (60%), rash, malaise, and laryngeal mucosal swelling (13%)
10 patients, 3 of them due to treatment side effects
Selumetinib (AZD6244) 
MEK-1/2 (one of MAPK), RAS, V600E BRAF
100 mg twice daily for 28-days cycles
Rash (77%), fatigue (49%), diarrhea (49%), and peripheral edema (36%)
Only 6 patients due to treatment side effects
Selective BRAF inhibitors
150 mg twice daily or 100 mg three times daily
skin papillomas (57%), hyperkeratosis (36%), alopecia (29%), elevated lipase (7%), grade 3 elevated amylase (7%), grade 3 fatigue (7%), grade 3 febrile neutropenia (7%), and grade 3 cutaneous squamous cell carcinoma (7%)
960 mg orally twice daily
squamous cell carcinoma of the skin (23.5%), lymphopenia (8%), and increased γ-glutamyl-transferase (8%)
To date, efforts based on pharmaceutically blocking MAPK increased progression-free survival in DTC and MTC . A recent single study showed that Lenvatinib achieved improvement in overall survival in older patients (> 65 years old) with advanced DTC in comparison to younger patients . Also the same study showed that this old age group suffered from higher toxicity in comparison to younger patients, rendering debatable clinical decisions in today’s practice. Other than systemic toxicity, the development of tumoral escape mechanisms to these drugs represents an additional limitation that should be considered more closely. Known tumoral escape cascades and mechanisms from MKI drugs include induction of either alternative signaling pathways or to tyrosine kinase receptor (TKR) upregulation on the tumoral cell surface [22–24]. As depicted in Fig. 1, the MAPK and PI3K-AKT cascades are overlapping, with upregulation of either pathway leading to the same end-result of tumor cell survival and proliferation. Some of the major PTC drivers, the RAS and RET/PTC oncogenes are essential components of MAPK pathway, with cross talk effects with the PI3K-AKT cascade (Fig. 1). The role of PI3K-AKT cascade in initiating and promoting the progression of thyroid tumors has been reviewed by Saji et al. [25, 26]. Activation of AKT leads to downstream activation of different proliferative targets including: forkhead family of transcription factor (FoxO), mammalian target of rapamycin (mTOR) and others .
Recent data, including the thyroid cancer gene atlas, suggests that other novel escape mechanisms may also exist, e.g. TKRs in other pathways have been found to be expressed in thyroid tumor cells, with evidence of downstream pro-proliferative actions [14, 27–29]. For example, studies on patient-derived thyroid tumors from patients with advanced cancer have demonstrated that a substantial percentage exhibit the increased presence of HER2/3 receptors as well as ALK rearrangements. These mutations tend to serve as tumoral escape mechanisms from the currently used MKIs through activating MEK the downstream effector of RAF  as depicted in Fig. 1. HER2/3 has been found to be capable of activating PI3k cascade as well (Fig. 1). In the light of these facts, a number of strategies using multiple pathways targeting agents are under study.
Upstream targeting of tumoral escape cascade
1. Targeting (ERBB-HER2/3)
A novel line of investigation involves targeting proposed upstream elements relative to MAPK/PI3K. HER2 (ErbB2) and HER3 (ErbB3) are tyrosine kinase receptors and member of the Epidermal growth factor receptor (EGFR) family . Their activation leads to downstream activation of both MAPK and PI3K cascade (Fig. 1). Preclinical data has shown that targeting these receptors by MKIs has represented an effective strategy, especially for breast cancer where these receptors are abundant. An escape mechanism identified in BRAF-mutant cells treated by Vemurafenib, is an overexpression of HER2/3 receptors and subsequent activation of mTOR cascades and MAPK  (Fig. 1). Therefore, current clinical efforts are assessing the role of HER receptors targeting in advanced thyroid cancer. NCT01947023 is a phase I trial assessing Lapatinib (HER2/3 blocker) in combination with Dabrafenib (BRAF inhibitor) for patients with advanced DTC and its primary results were published in ASCO 2017. Investigators included 15 evaluable patients with BRAF V600 mutations, 13 patients had DTC and 2 had ATC, prior MKI therapy was administered in 9/15 patients. Dabrafenib was given to all patients as 150 mg bid starting 2 weeks prior to Lapatinib. Doses of daily Lapatinib were escalated in a standard 3 + 3 design at (1) 750 mg; (2) 1250 mg; (3) 1500 mg. The reported partial response rate is 60% with a median PFS of 15 months (range, 2–34+ months). Only 1/15 patients developed grade III treatment-related toxicity, while dose-limiting toxicities were reported in only 1 patient with ATC and were unlikely related to drugs . In another trial, the pan-ERBB Inhibitor Neratinib (NCT 03065387) is being assessed for its effect in advanced solid tumors harboring any HER mutation, including thyroid cancer.
Targeting ALK translocations
Recently, ALK gene translocations were identified in patient-derived thyroid cancer cells  . In contrast to different ALK translocation fusions, identified in other tumor types, the STRN-ALK fusions encoding for striatin were identified in thyroid cancer cells . These hybrid mutations are found in up to 4% of ATC and 9% of poor differentiated thyroid cancer and lead to continuous activation of proliferating MAPK pathway through MEK activation  (Fig. 1). Two clinical reports describe the effect of selective ALK inhibitors in the setting of ATC. Godbert et al. reported in a case report the effect of Crizotinib (an ALK inhibitor that is FDA-approved for ALK positive non-small cell lung cancer) in a 71 year-old female with ALK-rearrangement ATC . This patient with stage IV, T4/N1A disease failed the initial treatment of concomitant chemoradiotherapy postoperatively (Cisplatin, Etoposide, and radiotherapy) with progression of metastatic pulmonary nodules. The second line chemotherapy of carboplatin and etoposide was administered with no clinical benefit after 3 cycles. Strikingly, as a last step approach, genetic profiling revealed ALK overexpression with intact EML4 gene. Based on this finding, Crizotinib (ALK inhibitor) was started and 3 months post-treatment, CT showed 90% regression in pulmonary nodules (RECIST criteria) and exceptional ECOG (Eastern Cooperative Oncology Group) performance status . NCT02289144 is the only recruiting clinical trial, so far, aiming to assess the role of Ceritinib in patients with advanced ATC with positive ALK abnormalities.
Downstream targeting of tumoral escape cascade
The growing knowledge of involvement of PI3K pathway in thyroid tumor cells pathogenesis and escape from conventional targeted therapy led to closer studying several components of this pathway. Among these components is mTOR (mammalian target of rapamycin), which when inhibited has led to cell proliferation suppression .
Two mTOR inhibitors have sufficiently favorable trial data that they have been approved by the FDA for clinical usage for other cancers: Temsirolimus in advanced renal carcinoma and Everolimus for advanced renal carcinoma, metastatic breast cancer, and progressive endocrine tumors of pancreatic origin (PNET) . Given observed clinical benefits of these drugs, and the belief that mTOR activation is a therapeutic target in thyroid cancer , these agents are being tested in the setting of advanced thyroid cancer. Early results from Phase II thyroid cancer trials give reason for hope. For example, NCT01025453, a Phase II study assessing the effect of Temsirolimus with Sorafenib in RAI-R thyroid cancer patients . Out of 37 patients, eight patients achieved partial response (PR), 21 had stable disease, while one patient developed progression and the remaining seven were un-evaluable. These results were independent from RAS or RAF mutation and reflect the importance of considering mTOR targeting as a promising approach for RAI-R and advanced thyroid cancer patients. The estimated completion date of this trial is December 2017 for final data collection and primary outcome measurement. In addition, NCT01141309, a Phase II Study evaluating the combination of Everolimus (mTOR inhibitor) and Sorafenib was presented at ASCO 2015 . Out of 41 patients with different types of progressive thyroid cancers included, only 38 were evaluable for the primary endpoint of clinical benefit at the date of publishing the results. In this cohort, 21 patients (55%) had PR, 14 patients (37%) achieved stable disease (SD), and three patients (8%) had progressive disease (PD). The subgroup and general toxicity assessment of this combination showed better response and less toxicity when compared to Sorafenib monotherapy, especially in the DTC subgroup.
NCT01263951 is an ongoing trial (enrolling at the time of this writing) testing the effect of this combination in DTC patients who progressed on Sorafenib therapy alone. Its preliminary results presented at ASCO 2015 showed remarkable reduction in Sorafenib-induced hand-foot syndrome (HFS) as a side effect, with SD as the best response achieved in most patients .
NCT02143726, an enrolling phase II study, assesses the efficacy and safety of Sorafenib with or without Everolimus in treating patients with advanced, RAI-R Hurthle cell thyroid cancer.
Finally, the abundance of PI3K/Akt/mTOR abnormalities in ATC spots this pathway as an attractive target for group of patients suffering from ATC . NCT02289144 is a recruiting trial aiming to assess the effect Ribociclib (targeting Retinoblastoma (RB) mutation) and Everolimus (mTOR inhibitor) in metastatic Rb + ATC patients. The rationale of targeting Rb in those patients is the abundance of intact RB in ATC patients . However, the awaited results of this trial may suggest new treatment strategies for ATC patients since retinoblastoma gene is still not considered a therapeutic target in ATC patients.
As mentioned earlier, ALK translocation and HER2/3 mutations are capable to induce their pro tumor proliferative effect through MEK, a downstream effector of MAPK pathway (Fig. 1) . This fact has attracted several trials to assess the effect of MEK blockage regardless of underlying genetic or molecular mutation.
The results of the phase II trial of Selumetinib (MEK 1–2 inhibitor)  yielded a tolerable safety profile in RAI-R PTC patients. However, it is to be noted that the effect of Selumetinib on progression-free survival (PFS) was affected by BRAF mutation status; where BRAF V600E mutants had a longer median PFS compared with patients with BRAF wild-type (WT) tumors. This suggest a preliminary evidence of stratified beneficence of Selumetinib based on underlying genetic abnormalities. Therefore more clinical trials with larger patients cohorts are addressing the efficacy of this drug in order to provide more clear evidences. NCT01843062 is currently an ongoing phase III trial aiming to assess the efficacy of Selumetinib vs placebo in DTC patients.
Other MEK inhibitors are being also assessed in advanced thyroid cancers. The primary results of NCT02034110 assessing Efficacy of Dabrafenib (BRAF inhibitor) and Trametinib (MEK inhibitor) in 16 patients with BRAF V600E (ATC) were published in ASCO 2017. The overall response rate (ORR) was reported to be 69% (11/16 patients). This regimen showed a controversial safety profile with grade 3–4 toxicities occurring in ≤19% of patients. However all of these toxicities were manageable .
The controversial preliminary results of NCT01723202 showed that adding Trametinib to Dabrafenib did not result in statistical significance in PR, ORR, SD, PFS as compared to Dabrafenib alone in BRAF mutated PTC patients . These contradicted results open the question if the concept of MEK inhibitionalone or the underlying tumoral phenotype is the reason behind these results. However, the final results of these trials and comparative analysis of MEK blocking effect in different thyroid tumor types will add more solid evidence.
Radioactive iodine (RAI) is widely used in the treatment of advanced follicular cell-derived thyroid cancers, but downregulation of the sodium-iodide symporter gene (SLC5A5, more commonly known as NIS) leads to resistance or RAI-R disease . A novel therapeutic strategy has been to pharmacologically induce re-expression of NIS, i.e. “redifferentiating” the cells such that they can be treated with radioiodine.
In this regard, in vitro studies showed that Retinoids (Vitamin A-derived retinoic acids) are able to induce thyroid tumors redifferentiating effects like induction of 5′-deiodinase , increased expression of NIS mRNA , and increased thyroglobulin level (Tg), known to be lost in de-differentiated thyroid cancers . Several clinical studies followed that principle for inducing RAI resensitization [37, 49–52]. The results of these studies indeed showed that retinoic acid therapy could, to a certain degree, induce RAI reuptake. Despite that finding, a true clinical beneficence in controlling underlying thyroid tumors has not been widely demonstrated, rendering the clinical application of retinoids in daily practice a doomed option.
A related line of investigation has examined whether Pax-8/PPARγ agonists might, in theory, upregulate NIS in RAI-R tumors. Based on pre-clinical data positively correlating Pax-8 (Paired box-8) and NIS promotor activity , along with the observation that PAX8-PPARγ translocations are present in 35% of FTC. Accordingly, a phase II study demonstrated that the Pax-8-PPARγ agonist Rosiglitazone (4 mg daily for 1 week, then 8 mg daily for 7 weeks) was associated with improved I-131 uptake in 4 out of 10 subjects .
Recently, the observation that constitutive activation of MAPK signaling causes transcriptional inhibition of thyroid hormone biosynthesis genes including NIS has led to the investigation of certain selective MAPK blocking agents as RAI resensitizer agents. .
In a phase II ‘proof of concept’ trial, Selumetinib (a MEK inhibitor) increased iodine uptake in 12 of 20 patients (quantitative I124 uptake). Eight of the 12 patients reached the dosimetry threshold for RAI therapy . The genetic subgroup analysis showed that all patients with RAS-mutated DTC (5 patients) responded to Selumetinib, while only four out of nine patients with BRAF mutation had a response. This difference could be attributed to either the effect of BRAF mutation on normal thyroid gene expression or to BRAF-induced TGFB (Transforming Growth Factor B) signaling, which represses NIS expression . Two ongoing trials, NCT01843062 and NCT02393690, both placebo-controlled trials with Selumetinib in locally-advanced, recurrent, or metastatic thyroid cancer will add more data to this existing pool of evidence, as well as a similar trial with the MEK inhibitor Trametinib, (NCT02152995).
Dabrafenib (BRAF inhibitor) restored RAI uptake in PTC advanced patients . Out of 10 selected patients, 60% (n = 6) showed increase RAI-131 uptake with 2/6 having partial response.
Several preclinical studies suggested promise for immunotherapy in the treatment of advanced follicular cell derived cancer as well as for MTC. While this general approach has been less developed in terms of clinical trial data than the MKI studies, there are several ongoing immunotherapy trials with clinical promise.
Changes in immune system relevant to thyroid cancer
Patterns in tumor-associated immune cells within the thyroid cancer microenvironment
Immune Component (Cell type)
Studies in Thyroid Cancer (with references)
PTC have been found to exhibit dense mast cell infiltration in comparison to normal thyroid tissues. This dense infiltration could be attributed to VEGF-A secretion by thyroid tumor cells which help in recruiting mast cells. Tumor recruiting mast cells play a role in tumor immune escape as these cells contribute to dedifferentiation, invasion, and angiogenesis of thyroid tumor through production of chemokines (CXCL1, CXCL10), histamine, and interleukin 8 [143–145].
Another proposed mechanism for tumor immune escape includes the overexpression of inhibitory checkpoint molecules in tumor associated T cells (Fig. 3). These molecules include PD-1, TIM-3, Lag-3, and TIGIT. The downstream inhibitory signaling of these molecules on T cells has been reviewed before  (Fig. 4). These molecules contribute to T cell dysfunction by affecting their production of the inflammatory cytokines IL-2, TNFα, and IFNγ. PD-1 molecule expression was associated with all classes of thyroid cancer with highest prevalence in anaplastic types. Regulatory T cells (Tregs) are a subpopulation of T cells known for their immune suppressive effects and tumor enhancing properties. Tregs exert these pro-tumor actions by expressing PD-1 and CTLA-4, another immune checkpoint modulator. Tregs were found in large amounts in advanced, locally-invasive DTC, lymph node metastases, and ATC. These findings support their role in tumor aggressiveness, and how targeting immune inhibitory Tregs can mediate better thyroid tumor control [74, 147–149].
Natural Killer cells (NK)
Patients with aggressive ATC or advanced and metastatic thyroid cancers were reported to have low peripheral blood NK cells in comparison to patients with benign lesions or other control patients. Introduction of IL-12 (an NK activating cytokine) in a murine model of BRAF-mutated thyroid cancer was helpful in restoring the tumor immune elimination properties. –Also, it is to be noted that NK cells could lyse anaplastic thyroid cells ex-vivo. It is hoped that these anti-tumoral activities of NK cells could be used in thyroid cancer immunotherapy [150–156].
Tumor associated macrophages (TAM)
These cells belong to the monocyte-macrophage lineage. There are two phenotypes of TAMs: M1 expressing IL-1, IL-12, and TNF-α, contributing to immune control over tumors; and M2 expressing IL-10 and CD163, promoting tumor progression and inhibition of tumor immune elimination. It was concluded that in PTC and poorly differentiated thyroid cancer, the density and presence of M2 TAMs correlated with tumor invasion and decreased survival. In anaplastic tumors, the TAMs form greater than 50% of tumor mass [157–159].
Immature dendritic cells expressing CD1a or S100 were found in PTC human tissue samples, and these cells failed to maintain an immune response to thyroid cancer cells [160–162]. A relation between TAMs and inability of dendritic cells to mature and present tumoral antigens has been proposed . Such relation suggests that targeting inhibitory TAMs could enhance dendritic cells differentiation. However, this concept remains yet to be validated in more pre-clinical studies as well as clinical trials.
Strategies for thyroid cancer immunotherapies
Many oncologic trials have focused on developing immunomodulating therapies to restore the functional ability of different immune cells against neoplastic cellsand, with promising results in several tumor types, including lung cancer, melanoma, and colon cancer [61, 62]. Recent efforts and advances in translational research led to proposing several strategies for immunomodulation in thyroid cancer and they will be reviewed here.
Inhibiting recruitment of tumor associated macrophages (TAM)
It was found that thyroid tumoral tissues expressed increased levels of CSF-1 and CCL-2 in human tissue samples . These molecules are known to be chemoattractants to TAMs. Since TAM represent more than 50% of anaplastic thyroid cancer volume, and to a lesser extent that of advanced DTC, blocking and targeting CCL-2/CCR2 and CSF-1/ CSF-1R pathways represents a promising approach (Fig. 3). This approach proposes not only inhibiting the recruitment of pro-tumor M2 phenotype TAMs, but also their repolarization into the M1 antitumor phenotype [64–66]. Therefore, the concept of depleting and repolarizing TAM to enhance anti-tumor immune response is the subject of many ongoing trials. In NCT01346358, CSF-1R antibody LY3022855 (also known as IMC-CS4) is tested against advanced solid tumors. NCT01525602 is recruiting patients with advanced solid tumors to test the effect of CSF-1R inhibitor (PLX3397) plus paclitaxel. Both studies include a cohort of thyroid patients.
Identification of tumor specific antigen and tumor neoantigens
Creating a cancer vaccine was recently the purpose of the cancer “Moonshot 2020” project . Identification of thyroid tumor specific or neoantigens could pave the path towards creating a successful vaccine for tumor specific dendritic cells and thyroid cancer specific T cells. Tumor-associated antigens (melanoma antigen encoding genes [MAGE], mucin-1 antigen [MUC1], and proto-oncogene c-MET) can be expressed along with thyroid specific proteins (thyroglobulin and thyroid peroxidase) in DTC [68–70].
Several studies showed that the burden of genetic alteration and thyroid tumor neo-antigen is more prevalent in poorly differentiated and anaplastic tumors than in early differentiated stages . Dendritic cell (DC) vaccines targeting the carcinoembryonic antigen (CEA), which is commonly expressed in MTC, have shown some clinical promise in these patients . In this study, mature DCs, generated from peripheral blood monocytes and loaded with calcitonin and carcinoembryonic antigen (CEA) were injected in a cohort of 7 patients. Calcitonin and CEA were remarkably decreased in 3/7 patients with one of these three showing complete regression of metastatic hepatic and pulmonary nodules .
Other efforts of clinical targeting specific thyroid antigens is also under investigation; NCT01856920 is testing GI-6207, a vaccine made from baker’s yeast targeting the CEA in patients with MTC. NCT02239861 is recruiting patients to test specific adoptive cytotoxic T cells targeting several tumor antigens (NY-ESO-1, MAGEA4, PRAME, survivin, and SSX) in patients with advanced solid tumors, including thyroid cancer patients.
Blocking and inhibiting immune checkpoints
Dual targeting of the immune system in thyroid tumor microenvironment could, in theory, maximize the clinical benefits. This approach has been adopted by several trials: NCT02452424 is testing CSF-1R inhibitor (PLX3397) plus PD-1 inhibitor (Pembrolizumab) against advanced melanoma and other solid tumors, including thyroid. NCT02718911 is testing another CSF-1R inhibitor (LY3022855) plus Tremelimumab or Durvalumab (PD-1 inhibitors) in solid tumors.
Restoring the tumor phagocytic ability of TAM and enhancing tumor antigen presentation
Generally, most cancer cells, including thyroid cancers, were found to express an inhibitory receptor coined CD47, whose ligand is TAM signal-regulatory protein α (SIRPα). This receptor-ligand interaction leads to inhibiting the phagocytic ability of TAM, and impaired tumor antigen presentation by dendritic cells. In mouse models, blocking SIRPα/CD47 was successful in inducing tumor regression. Therefore, blocking CD47 by monoclonal antibodies or targeting SIRPα, represents an approach to reverse the immunoinhibitory effect of this pathway [76–78]. This concept was proven pre-clinically, where blocking CD47 in human thyroid cancer cell lines showed apoptotic effects . However, clinical trials assessing CD47 targeting are needed to assess the clinical efficacy of this approach.
MKIs and immunotherapy
Recent data showing a role for kinase inhibitors in immune modulation brings the promise that perhaps both strategies can be utilized simultaneously to achieve better responses in advanced thyroid cancer. Regulatory T cells express VEGFR-2, and both VEGF-A and BRAF-V600E are associated with upregulation of PD-1 expression, leading to inhibition of cytotoxic T cells [80–82].
Therefore, currently available MKIs could potentially reverse the inhibitory effects of pathologic kinase activities on the immune system.
Immunotherapy trials addressing thyroid cancer
CSF-1R antibody LY3022855 (also known as IMC-CS4) is tested in advanced solid tumors, including thyroid cancer
Testing the effect of CSF-1R inhibitor (PLX3397) plus paclitaxel in patients with advanced solid tumors, including thyroid cancer
Testing GI-6207, a vaccine made from baker’s yeast, targeting the CEA in patients with MTC
Testing specific adoptive cytotoxic T cells targeting several tumor antigens (NY-ESO-1, MAGEA4, PRAME, survivin, and SSX) in patients with advanced solid tumors, including thyroid cancer patients
Testing Pembrolizumab effect as monotherapy in advanced solid tumor patients, including a cohort of thyroid cancer patients
Testing CSF-1R inhibitor (PLX3397) plus PD-1 inhibitor (Pembrolizumab) against advanced melanoma and other solid tumors, including thyroid
Testing another CSF-1R inhibitor (LY3022855) plus Tremelimumab or Durvalumab (PD-1 inhibitors) in solid tumors
Open label - two cohorts - phase I, II trial assessing the role of Sulfatinib in advanced MTC and RAI-R DTC
Phase IB/II trial, currently recruiting patients with solid tumors to assess the maximum tolerated dose (MTD) for Lenvatinib in combination with Pembrolizumab during phase IB of the trial. A subsequent expansion phase II trial will evaluate the safety and efficacy of this combination
Testing the effect of combining the PDL-1 inhibitor Atezolizumab, plus the mitogen-activated protein kinase (MAPK) inhibitor, Cobimetinib, in Locally Advanced or Metastatic Solid Tumors
Phase IB trial investigating PD-L1 antibody Atezolizumab plus mutant BRAF inhibitor Vemurafenib for patients with BRAFV600 mutation-positive metastatic melanoma (even though this trial has no thyroid patients, its results will help in designing future thyroid trials using such a combination based on pharmacodynamics and kinetics of this study)
Based on current evidences and preliminary results of clinical trials assessing new treatment strategies, clustering patients with advanced thyroid cancers who failed conventional treatment options, according to their underlying molecular profile involved in disease development, will definitely help optimizing treatment decisions in clinical scenarios. This fact can be attributed to the widely varying molecular nature of different escape mechanisms from drugs targeting MAPK. The awaited clinical trials mentioned in this review (Additional file 1: Table S1) will definitely help implement new treatment strategies for these patients.
Also, there is clearly much work to be done to identify novel therapeutic targets and to develop strategies for treating advanced thyroid cancer. Pre-clinical data suggests a number of areas that could be developed in the coming years. For example, Histone Deacetylase Inhibitors (HDACIs) have been shown to increase expression of tumor suppressor genes in in vitro models of MTC [85–88]. Enthusiasm is tempered by two recent trials using the HDACI Valproic Acid in RAI-R DTC and ATC with negative results [89, 90], and yet other HDACIs may have potential based on very recent pre-clinical data,; for example CUDC-907, a dual inhibitor of HDACs and PI3k pathway, showing apoptotic effects in thyroid cancer cell lines in vitro and significant inhibition of growth and metastasis in a metastatic mouse model .
Another area to be developed is in the identification of biomarkers: a biomarker predicting the likelihood of clinical beneficence from targeted therapy is still lacking. One promising approach is looking at miRNAs, with certain expression patterns possibly providing a signature related to different clinicopathological features of thyroid cancer . Finally, investigators are using kinome profiling, studying kinase complement of the human genome, combined with other transcriptional phosphoproteomics studies, to look for new treatment targets and strategies enhancing the currently available MKIs. One recent report identified SRC kinases as targets for invasive thyroid tumors using kinase phosphorylation assay . Another report, using global phosphoproteomics analysis, identified CK2 (Caseine Kinsase 2) as a survival mechanism after BRAF-MEK signaling blockade . These markers might be developed as tools to monitor response to different MKIs therapies targeting MAPK. An interesting report by Martinez et al. identified new molecular targets using mass spectrometry proteomics on a large scale ; in this study, TGFβ-induced protein ig-h3 (TGFBI) was found to be overexpressed in FTC. PTC samples, in comparison to FTC and normal tissue samples, was found to overexpress the extracellular protein Decorin, Tenascin, and AGR-2 . These findings can provide future targets for new therapeutics.
Thyroid cancer patients with advanced disease still do not have adequate treatment options, but the immediate and long-term future of therapy in this area looks bright. As research leads to a better understanding of underlying molecular changes in these patients, it should become increasingly possible to offer individualized, targeted therapy in their treatment protocols. With a number of MKIs being studied that can target the key pathways and escape mechanisms driving advanced thyroid cancer, and with the dawn of the age of immunotherapy, it can be hoped and perhaps even expected that soon novel therapeutics arise offering better long-term survival for these patients.
This study is Supported by the grant for US-egyptian research cooperative grant cycle 17 STDF144. We would like to thank Nardine Hany for her help in designing the figures for that article.
GN did the literature search and writing. GN, MM, BK, and WA did the concept design and editing for review. All authors reviewed and agreed to the final version of the manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801–7.PubMedView ArticleGoogle Scholar
- Pellegriti G, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:10.View ArticleGoogle Scholar
- Liska J, et al. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul. 2005;39(3):73–83.PubMedGoogle Scholar
- Xu B, Ghossein R. Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol. 2016;27(3):205–12.PubMedView ArticleGoogle Scholar
- Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–80.PubMedView ArticleGoogle Scholar
- Hadoux J, et al. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64–71.PubMedView ArticleGoogle Scholar
- Spitzweg C, et al. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014;2(10):830–42.PubMedView ArticleGoogle Scholar
- Cabanillas ME, et al. Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract. 2016;12(6):511–8.PubMedView ArticleGoogle Scholar
- American Cancer Society. Cancer Facts & Figures. Atlanta: G.A.C.S; 2017.Google Scholar
- Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3–20.PubMedView ArticleGoogle Scholar
- Bikas A, et al. Targeted therapies in thyroid cancer: an extensive review of the literature. Expert Rev Clin Pharmacol. 2016:1–15.Google Scholar
- Widakowich C, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12(12):1443–55.PubMedView ArticleGoogle Scholar
- Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(Suppl 2):S37–43.PubMedPubMed CentralView ArticleGoogle Scholar
- Agrawal N, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.PubMed CentralView ArticleGoogle Scholar
- Cooper DS, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.PubMedView ArticleGoogle Scholar
- Haugen BR, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedPubMed CentralView ArticleGoogle Scholar
- Bernet V, Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs. 2014;19(2):225–41.PubMedView ArticleGoogle Scholar
- Carneiro RM, et al. Targeted therapies in advanced differentiated thyroid cancer. Cancer Treat Rev. 2015;41(8):690–8.PubMedView ArticleGoogle Scholar
- Viola D, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185–205.PubMedView ArticleGoogle Scholar
- Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016;13(7):403–16.PubMedView ArticleGoogle Scholar
- Brose MS, et al. Effect of age on the efficacy and safety of Lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692–9.PubMedView ArticleGoogle Scholar
- Lo RS. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res. 2012;22(6):945–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle. 2009;8(1):18–22.PubMedPubMed CentralView ArticleGoogle Scholar
- Sennino B, DM MD. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012;12(10):699–709.PubMedPubMed CentralView ArticleGoogle Scholar
- Xing M. Genetic alterations in the Phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697–706.PubMedPubMed CentralView ArticleGoogle Scholar
- Saji M, Ringel MD. The PI3K-AKT-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1):20–8.PubMedView ArticleGoogle Scholar
- Luo M, Fu LW. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res. 2014;4(6):608–28.PubMedPubMed CentralGoogle Scholar
- Ruggeri RM, et al. HER2 analysis in sporadic thyroid cancer of follicular cell origin. Int J Mol Sci. 2016;17(12)Google Scholar
- Chou A, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol. 2015;39(5):652–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Montero-Conde C, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discov. 2013;3(5):520–33.PubMedPubMed CentralView ArticleGoogle Scholar
- Sherman EJ, Ho AL, Baxi SS, Dunn L, Korte SH, et al. Combination of dabrafenib (DAB). J Clin Oncol. 2017;35(15 suppl):6085.Google Scholar
- Kelly LM, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(11):4233–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Murugan AK, Xing M. Anaplastic thyroid Cancers Harbor novel oncogenic mutations of the ALK gene. Cancer Res. 2011;71(13):4403–11.PubMedPubMed CentralView ArticleGoogle Scholar
- Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 0000, 26(22):3291–310.Google Scholar
- Godbert Y, et al. Remarkable response to Crizotinib in woman with anaplastic lymphoma kinase–rearranged anaplastic thyroid carcinoma. J Clin Oncol. 2015;33(20):e84–7.PubMedView ArticleGoogle Scholar
- Pópulo H, Lopes JM, Soares P. The mTOR Signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–918.PubMedPubMed CentralView ArticleGoogle Scholar
- Souza EC, Ferreira AC, Carvalho DP. The mTOR protein as a target in thyroid cancer. Expert Opin Ther Targets. 2011;15(9):1099–112.PubMedView ArticleGoogle Scholar
- EJ Sherman, AL Ho, MG. Fury, SS. Baxi, S Haque, SH Korte, S Smith-Marrone, H Xiao, RA Ghossein, JA. Fagin, DG. Pfister. A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. asco meeting 2012. abstract#5514.Google Scholar
- EJ Sherman, AL Ho, MG. Fury, SS. Baxi, L Dunn, JS Lee, BL Lipson, DG. Pfister, Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study. ASCO 2015. Abstract#6069.Google Scholar
- M.S. Brose, A.B. Cohen, M. Yarchoan, A. B. Cohen, K. Harlacker, N.A. Dyanick, Z.A. Posey, R. Makani, P. Prajapati, L.M. Zifchak, C. Grande, C.M. Squillante. A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. ASCO 2015. Abstract# 6072.Google Scholar
- Anwar F, et al. Retinoblastoma Expression in Thyroid Neoplasms. Mod Pathol. 13(5):562–9.Google Scholar
- Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.PubMedView ArticleGoogle Scholar
- Hayes DN, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056–65.PubMedPubMed CentralView ArticleGoogle Scholar
- Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, et al. Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC). J Clin Oncol. 2017;35(15 suppl):6023.Google Scholar
- Shah MH, Wirth L, Wirth LJ, Daniels GA, De Souza JA, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017;35(15 suppl):6022.Google Scholar
- Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012;135(3):355–70.PubMedPubMed CentralView ArticleGoogle Scholar
- Van Herle AJ, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab. 1990;71(3):755–63.PubMedView ArticleGoogle Scholar
- Schmutzler C, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997;240(3):832–8.PubMedView ArticleGoogle Scholar
- Simon D, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29(6):775–82.PubMedView ArticleGoogle Scholar
- Fernandez CA, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Investig. 2009;32(3):228–33.View ArticleGoogle Scholar
- Zhang Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun. 2007;28(4):251–5.PubMedView ArticleGoogle Scholar
- Handkiewicz-Junak D, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res. 2009;2(1):8.PubMedPubMed CentralView ArticleGoogle Scholar
- Presta I, et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer. 2005;5:80.PubMedPubMed CentralView ArticleGoogle Scholar
- Kebebew E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery. 140(6):960–7.Google Scholar
- Durante C, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840–3.PubMedView ArticleGoogle Scholar
- Ho AL, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32.PubMedPubMed CentralView ArticleGoogle Scholar
- Riesco-Eizaguirre G, et al. The BRAF<sup>V600E</sup> oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009;69(21):8317–25.PubMedView ArticleGoogle Scholar
- Rothenberg SM, et al. Redifferentiation of iodine-refractory <em>BRAF</em> V600E-mutant metastatic papillary thyroid cancer with Dabrafenib. Clin Cancer Res. 2015;21(5):1028–35.PubMedView ArticleGoogle Scholar
- Kaufmann SHE. Immunology's foundation: the 100-year anniversary of the Nobel prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. 2008;9(7):705–12.PubMedView ArticleGoogle Scholar
- Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.PubMedView ArticleGoogle Scholar
- Khalil DN, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273–90.PubMedPubMed CentralView ArticleGoogle Scholar
- Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim S, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab (Seoul). 2013;28(3):192–8.View ArticleGoogle Scholar
- Ryder M, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013;8(1):e54302.PubMedPubMed CentralView ArticleGoogle Scholar
- Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.PubMedPubMed CentralView ArticleGoogle Scholar
- Withers S, et al. Targeting Tumor-Associated Monocytes/Macrophages (TAMs) through the CSF-1/CSF-1R Pathway Restores Sensitivity of Advanced Thyroid Cancers to Cytotoxic Chemotherapy, in Metastasis and Tumor Progression: Cells Doing What They Shouldn't. p. OR45–6.Google Scholar
- Wang X. Cancer moonshot 2020: a new march of clinical and translational medicine. Clinical and Translational Medicine. 2016;5:11.PubMedPubMed CentralView ArticleGoogle Scholar
- Martins MB, et al. CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors. J Immunol Res. 2014;2014:921864.PubMedPubMed CentralView ArticleGoogle Scholar
- Milkovic M, Sarcevic B, Glavan E. Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr Pathol. 2006;17(1):45–52.PubMedView ArticleGoogle Scholar
- Bieche I, et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid. 1997;7(5):725–31.PubMedView ArticleGoogle Scholar
- Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–66.PubMedPubMed CentralView ArticleGoogle Scholar
- Schott M, et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab. 2001;86(10):4965–9.PubMedView ArticleGoogle Scholar
- Topalian SL, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.PubMedPubMed CentralView ArticleGoogle Scholar
- French JD, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97(6):E934–43.PubMedPubMed CentralView ArticleGoogle Scholar
- Mehnert AM, Varga A, Brose M, Aggarwal RR, Lin C-C, Prawira A, et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol. 2016;34((suppl; abstr 6091)Google Scholar
- Jaiswal S, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–85.PubMedPubMed CentralView ArticleGoogle Scholar
- Willingham SB, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhao XW, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A. 2011;108(45):18342–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Rath GM, et al. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta. 2006;1763(10):1125–34.PubMedView ArticleGoogle Scholar
- Terme M, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539–49.PubMedView ArticleGoogle Scholar
- Angell TE, et al. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014;24(9):1385–93.PubMedPubMed CentralView ArticleGoogle Scholar
- Voron T, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–48.PubMedPubMed CentralView ArticleGoogle Scholar
- Cabrera R, et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2013;62(4):737–46.PubMedView ArticleGoogle Scholar
- Chen ML, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer. 2014;134(2):319–31.PubMedView ArticleGoogle Scholar
- Woyach JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(1):164–70.PubMedView ArticleGoogle Scholar
- Brest P, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):711–9.PubMedView ArticleGoogle Scholar
- Xu Y, et al. Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol. 2015;8(7):8291–7.PubMedPubMed CentralGoogle Scholar
- Damaskos C, et al. Histone deacetylase inhibitors: a novel therapeutic weapon against medullary thyroid cancer? Anticancer Res. 2016;36(10):5019–24.PubMedView ArticleGoogle Scholar
- Nilubol N, et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clin Endocrinol. 2017;86(1):128–33.View ArticleGoogle Scholar
- Catalano MG, et al. Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase II/III trial. Int J Endocrinol. 2016;2016:8.View ArticleGoogle Scholar
- Kotian S, et al. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. Clin Cancer Res. 2017;23(17):5044–54.PubMedView ArticleGoogle Scholar
- Li X, Wang Z. The role of noncoding RNA in thyroid cancer. Gland Surg. 2012;1(3):146–50.PubMedPubMed CentralGoogle Scholar
- Cho NL, et al. Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers. Biochem Biophys Res Commun. 2012;421(3):508–13.PubMedView ArticleGoogle Scholar
- Parker R, Clifton-Bligh R, Molloy MP. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Mol Cancer Ther. 2014;13(7):1894–906.PubMedView ArticleGoogle Scholar
- Martinez-Aguilar J, Clifton-Bligh R, Molloy MP. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy. Sci Rep. 2016;6:23660.PubMedPubMed CentralView ArticleGoogle Scholar
- Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol. 2005;16(3):163–72.PubMedView ArticleGoogle Scholar
- Cohen Y, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625–7.PubMedView ArticleGoogle Scholar
- Fagin JA. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc. 2005;116:259–69. discussion 269-71PubMedPubMed CentralGoogle Scholar
- Kimura ET, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454–7.PubMedGoogle Scholar
- Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292–306.PubMedView ArticleGoogle Scholar
- Namba H, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88(9):4393–7.PubMedView ArticleGoogle Scholar
- Nikiforova MN, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–404.PubMedView ArticleGoogle Scholar
- Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.PubMedView ArticleGoogle Scholar
- Xing M, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–9.PubMedView ArticleGoogle Scholar
- Basolo F, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10(1):19–23.PubMedView ArticleGoogle Scholar
- Ezzat S, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid. 1996;6(5):409–16.PubMedView ArticleGoogle Scholar
- Fagin JA. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol. 2002;16(5):903–11.PubMedGoogle Scholar
- Hara H, et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994;116(6):1010–6.PubMedGoogle Scholar
- Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4(10):1474–9.PubMedView ArticleGoogle Scholar
- Suarez HG, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990;5(4):565–70.PubMedGoogle Scholar
- Zhu Z, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71–7.PubMedView ArticleGoogle Scholar
- Fusco A, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987;328(6126):170–2.PubMedView ArticleGoogle Scholar
- Grieco M, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–63.PubMedView ArticleGoogle Scholar
- Jhiang SM, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology. 1996;137(1):375–8.PubMedView ArticleGoogle Scholar
- Powell DJ Jr, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998;58(23):5523–8.PubMedGoogle Scholar
- Santoro M, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 1996;12(8):1821–6.PubMedGoogle Scholar
- Santoro M, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9(2):509–16.PubMedGoogle Scholar
- Santoro M, et al. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 1993;4(2):77–84.PubMedGoogle Scholar
- Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8(6):345–54.PubMedView ArticleGoogle Scholar
- French CA, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol. 2003;162(4):1053–60.PubMedPubMed CentralView ArticleGoogle Scholar
- Giordano TJ, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res. 2006;12(7 Pt 1):1983–93.PubMedView ArticleGoogle Scholar
- Gregory Powell J, et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene. 2004;23(20):3634–41.PubMedView ArticleGoogle Scholar
- Kroll TG, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289(5483):1357–60.PubMedView ArticleGoogle Scholar
- Nikiforova MN, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.PubMedView ArticleGoogle Scholar
- Reddi HV, et al. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology. 2007;148(3):932–5.PubMedView ArticleGoogle Scholar
- Landa I, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6.PubMedPubMed CentralView ArticleGoogle Scholar
- Malaguarnera R, et al. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab. 2014;99(10):E1976–87.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143–55.PubMedPubMed CentralGoogle Scholar
- Taccaliti A, et al. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics. 2011;12(8):618–25.View ArticleGoogle Scholar
- Cohen EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–13.PubMedPubMed CentralView ArticleGoogle Scholar
- Sherman SI, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42.PubMedView ArticleGoogle Scholar
- Carr LL, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Bible KC, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–72.PubMedPubMed CentralView ArticleGoogle Scholar
- Lim SM, et al. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer. 2015;51(12):1588–95.PubMedView ArticleGoogle Scholar
- de Groot JWB, et al. A phase II trial of Imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–9.PubMedView ArticleGoogle Scholar
- Falchook GS, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015;25(1):71–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Brose MS, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–82.PubMedPubMed CentralView ArticleGoogle Scholar
- Cunha LL, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol. 2012;77(6):918–25.View ArticleGoogle Scholar
- French JD, et al. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95(5):2325–33.PubMedPubMed CentralView ArticleGoogle Scholar
- Kumar A, et al. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994;4(2):199–202.PubMedView ArticleGoogle Scholar
- Pacini F, et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol. 1988;119(3):373–80.PubMedGoogle Scholar
- Spencer CA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83(4):1121–7.PubMedGoogle Scholar
- Melillo RM, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203–15.PubMedView ArticleGoogle Scholar
- Proietti A, et al. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid. 2011;21(11):1209–15.PubMedView ArticleGoogle Scholar
- Visciano C, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-slug pathway. Oncogene. 2015;34(40):5175–86.PubMedView ArticleGoogle Scholar
- Speiser DE, Ho P-C, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599–611.PubMedView ArticleGoogle Scholar
- Bastman JJ, et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2016;101(7):2863–73.PubMedPubMed CentralView ArticleGoogle Scholar
- Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.PubMedView ArticleGoogle Scholar
- Severson JJ, et al. PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunol Res. 2015;3(6):620–30.PubMedPubMed CentralView ArticleGoogle Scholar
- Angell TE, et al. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014;20(23):6034–44.PubMedPubMed CentralView ArticleGoogle Scholar
- Boros P, Balazs G, Szegedi G. Natural killer activity in thyroid cancer patients. Haematologia (Budap). 1987;20(3):189–93.Google Scholar
- Gogali F, et al. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab. 2012;97(5):1474–82.PubMedView ArticleGoogle Scholar
- Modi J, et al. Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab. 2003;88(9):4418–25.PubMedView ArticleGoogle Scholar
- Parhar RS, et al. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model. Lab Investig. 2016;96(1):89–97.PubMedView ArticleGoogle Scholar
- Wennerberg E, et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin Cancer Res. 2014;20(22):5733–44.PubMedView ArticleGoogle Scholar
- Xu X, et al. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab. 2006;91(7):2704–12.PubMedView ArticleGoogle Scholar
- Qing W, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid. 2012;22(9):905–10.PubMedPubMed CentralView ArticleGoogle Scholar
- Ryder M, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15(4):1069–74.PubMedPubMed CentralView ArticleGoogle Scholar
- Caillou B, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011;6(7):e22567.PubMedPubMed CentralView ArticleGoogle Scholar
- Batistatou A, Zolota V, Scopa CD. S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions. Endocr Pathol. 2002;13(2):111–5.PubMedView ArticleGoogle Scholar
- Ugolini C, et al. Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid. 2007;17(5):389–93.PubMedView ArticleGoogle Scholar
- Scarpino S, et al. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol. 2000;156(3):831–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Baba T, et al. Novel process of intrathymic tumor-immune tolerance through CCR2-mediated recruitment of Sirpalpha+ dendritic cells: a murine model. PLoS One. 2012;7(7):e41154.PubMedPubMed CentralView ArticleGoogle Scholar